Molecular characterization and experimental models of chordoma: Foundations for rational therapy development
Christian Godinez1, Matthew Holman1, Emilija Sagaityte1
1Department of Neurosurgery, Brown University, The Warren Alpert Medical School, Providence, RI, United States.
Abstract:
Advancing therapeutic strategies for chordoma requires a deep molecular understanding of tumor biology, supported by robust and reproducible experimental models. This chapter reviews recent progress in the development of in vitro and in vivo chordoma systems, including novel cell lines, genetically engineered models, and patient-derived xenografts. We detail the molecular and epigenetic features that underpin chordoma pathogenesis and resistance to therapy. Special attention is given to the design and testing of combinatorial therapeutic approaches-including immunotherapies, epigenetic modulators, and hydrogel-based drug delivery systems-that target distinct molecular vulnerabilities. Together, these innovations provide a translational framework for next-generation therapies tailored to the unique biology of chordoma.
Insights
Developing new chordoma (rare bone cancer) treatments needs better models and understanding of tumor biology. This review covers new cell lines, engineered models, and therapies targeting molecular weaknesses for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Translational Medicine
Background:
- Chordoma (rare bone cancer) treatment advances require a deeper understanding of tumor biology.
- Robust and reproducible experimental models are crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To review recent progress in developing in vitro and in vivo chordoma models.
- To detail molecular and epigenetic features driving chordoma pathogenesis and therapy resistance.
- To highlight combinatorial therapeutic approaches targeting molecular vulnerabilities.
Main Methods:
- Review of novel cell lines, genetically engineered models, and patient-derived xenografts for chordoma research.
- Analysis of molecular and epigenetic characteristics of chordoma.
- Evaluation of combinatorial therapies including immunotherapies, epigenetic modulators, and hydrogel-based drug delivery systems.
Main Results:
- Development of novel experimental models (cell lines, GEMMs, PDXs) enhances chordoma research.
- Identification of key molecular and epigenetic drivers of chordoma pathogenesis and treatment resistance.
- Demonstration of efficacy for combinatorial therapies targeting specific molecular vulnerabilities.
Conclusions:
- Innovative experimental models and a deeper understanding of chordoma biology are essential for advancing treatment.
- Combinatorial therapeutic strategies show promise for overcoming treatment resistance in chordoma.
- These advancements provide a framework for developing next-generation, personalized chordoma therapies.
